Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database
Journal of Infection and Chemotherapy · 2025
DOI: 10.1016/j.jiac.2024.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Infection and Chemotherapy, 2025. Verfasst von Koki Takeda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi Tokyo, 202-8585, Japan; Research Instit…. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Sulfamethoxazole/trimethoprim (ST) is a first-line drug for preventing pneumocystis pneumonia (PCP). Several small-scale studies have suggested the usefulness of the low-dose regimen of ST (200/40 mg/day) over the standard-dose one (400/80 mg/day). Thus, this study aimed to investigate the efficacy and safety of low-dose and standard-dose regimens of ST in preventing PCP in patients with non human immunodeficiency virus infection using a large-scale electronic medical record database. METHODS: This retrospective study included patients who received ST prophylaxis for PCP registered in the RWD database between June 2007 and February 2023. Patients received either standard-dose (400/80 mg/day) or low-dose (200/40 mg/day) regimen groups. The incidence of cases initiated PCP therapeutic dose (ci-PCPTD) (ST ≥ 3600/720 mg/day) and adverse events (AEs) was evaluated, and risk factors for ci-PCPTD were investigated. RESULTS: A total of 11,384 patients received the standard-dose, whereas 7973 received the low-dose regimen groups. No significant difference in the cumulative incidence of ci-PCPTD was observed between the standard-dose (0.67%) and low-dose regimen group (0.47%). Lung disease was a significant risk factor for ci-PCPTD. The cumulative incidence of ci-PCPTD in patients with acute exacerbation of interstitial pneumonia was 1.3% in both groups, and no significant difference was observed between the two groups. The low-dose regimen group had a lower incidence of all AEs than the standard-dose regimen group. CONCLUSION: These results based on a large-scale electronic medical record database provide important evidence supporting the clinical significance of low-dose regimen of ST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi Tokyo, 202-8585, Japan; Research Institute of Pharmaceutical Science, Faculty of Pharmacy, Musashino Universi…
- Department of Pharmacy, Mie Prefectural Shima Hospital, Ugata 1257 Ago-cho, Shima-shi Mie, 517-0501, Japan.
Zitieren
APA
Takeda, K., Okada, A., Sera, S., Oishi, T., & Nagai, N. (2025). Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database. Journal of Infection and Chemotherapy. https://doi.org/10.1016/j.jiac.2024.10.005
Vancouver
Takeda K, Okada A, Sera S, Oishi T, Nagai N. Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database. Journal of Infection and Chemotherapy. 2025. doi:10.1016/j.jiac.2024.10.005
BibTeX
@article{Takeda2025,
author = {Takeda, Koki and Okada, Akira and Sera, Shoji and Oishi, Teruki and Nagai, Naomi},
title = {Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database},
journal = {Journal of Infection and Chemotherapy},
year = {2025},
doi = {10.1016/j.jiac.2024.10.005}
}
EUVIMED